(Q50672722)

English

Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.

scientific article published in May 2016

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

arterial hypertension

0 references

pulmonary vascular disease

1 reference

based on heuristic

inferred from title

author name string

Georg Hansmann

1

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

Christian Apitz

2

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

language of work or name

0 references

publication date

1 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

102 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

ii67-85

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endors

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pediatric pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Nocturnal oxygen therapy in patients with the Eisenmenger syndrome

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Does anticoagulation in Eisenmenger syndrome impact long-term survival?

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The Eur

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Outcomes in children with idiopathic pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Vasodilator therapy for primary pulmonary hypertension in children

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Role of pharmacologic tests in the treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Effects of long-term bosentan in children with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Macitentan and morbidity and mortality in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Does intravenous sildenafil clinically ameliorate pulmonary hypertension during perioperative management of congenital heart diseases in children? - a prospective randomized study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Initial experience with tadalafil in pediatric pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Riociguat for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Riociguat for pulmonary arterial hypertension associated with congenital heart disease.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Tadalafil therapy for pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Childhood idiopathic pulmonary arterial hypertension: a national cohort study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Long-term therapy with inhaled iloprost in patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Beraprost therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Inhaled iloprost for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Atrial septostomy in patients with pulmonary hypertension: should it be recommended?

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Interventional and surgical modalities of treatment in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Atrial septostomy improves survival in select patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Patent ductus arteriosus stenting (transcatheter Potts shunt) for palliation of suprasystemic pulmonary arterial hypertension: a case series

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Creation of a functional Potts shunt by stenting the persistent arterial duct in newborns and infants with suprasystemic pulmonary hypertension of various etiologies.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Transcatheter creation of a reverse Potts shunt in a patient with severe pulmonary arterial hypertension associated with Moyamoya syndrome.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension).

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Identification of treatment goals in paediatric pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

The challenges in paediatric pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Registries for paediatric pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-309103

21 January 2018

Identifiers

10.1136/HEARTJNL-2015-309103

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/27053700

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50672722&oldid=1516161172"